Making personalized medicine come true
Welcome to BIOCRATES Life Sciences AG, a leading company in the field of diagnostic biomarker research.
Biomarkers are rapidly becoming the main drivers of innovation in the 21st century. Because they improve the potential to tailor treatment to the specific needs of individual patients, they are a critical prerequisite to personalized medicine.
Biocrates identifies and quantifies endogenous metabolites in body fluid or tissue samples and develops them into powerful biomarkers. By focusing on metabolites, we look at the functional endpoints of diseases and drug action—a technology called metabolomics.
Cutting-edge biomarker research stands to benefit everyone.
- Research organizations will be able to enrich their diagnostics and drug development programs and save costs by better targeting their projects.
- Physicians will be able to predict disease risk more reliably, establish diagnoses earlier, and tailor treatments more individually.
- Patients will benefit from treatments that are more efficacious and have fewer side effects.
- Investors can expect to be part of our cutting-edge science combined with sustained value creation.
Biocrates—bringing society one step closer to the goal of personalized medicine.
